Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer
Journal article published in 2013 by
Manfred Welslau,
Veronique Diéras,
Joo-Hyuk Sohn 
,
Sara A. Hurvitz,
Deepa Lalla,
Liang Fang,
Betsy Althaus,
Ellie Guardino,
David Miles
,
Sara A. Hurvitz,
Deepa Lalla,
Liang Fang,
Betsy Althaus,
Ellie Guardino,
David Miles
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 